HVIVO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.25 GBX | +4.46% |
|
+6.95% | +23.16% |
| 07-17 | HVIVO reports 31% revenue jump; relocation to improve efficiencies | AN |
| 07-17 | Transcript : HVIVO plc - Analyst/Investor Day |
Presenter SpeechYamin Khan (Executives)All right. Thank you, everyone, for attending our CMD t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO plc runs challenge trials in London with a new 50 quarantine bedroom, state-of-the-art facilities opening in Canary Wharf in 2024, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
Calendar
24/09/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.2925
GBP
Average target price
0.3636
GBP
Spread / Average Target
+24.30%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.16% | 247M | |
| +24.74% | 47.96B | |
| -0.47% | 42.45B | |
| +43.96% | 41.47B | |
| +25.40% | 31.6B | |
| +17.96% | 28.63B | |
| -4.47% | 28.03B | |
| +50.73% | 14.56B | |
| +42.56% | 14.14B | |
| +1.46% | 12.58B |
- Stock Market
- Equities
- HVO Stock
- News hVIVO plc
- Transcript : HVIVO plc - Analyst/Investor Day
